M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Richard D. Gordon,Eduardo A. Albornoz,Daniel C. Christie,Monica R. Langley,Vinod Kumar,Susanna Mantovani,Susanna Mantovani,Avril A. B. Robertson,Mark S. Butler,Dominic B. Rowe,Luke A. J. O'Neill,Anumantha G. Kanthasamy,Kate Schroder,Mark E. Cooper,Mark E. Cooper,Trent M. Woodruff +15 more
TL;DR: It is shown that activation of the microglial NLR family pyrin domain containing 3 (NLRP3) inflammasome is a common pathway triggered by both fibrillar α- synuclein and dopaminergic degeneration in the absence of α-synuclein aggregates.
Journal ArticleDOI
Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes
Sophia Zoungas,John Chalmers,Bruce Neal,Laurent Billot,Qiang Li,Yoichiro Hirakawa,Hisatomi Arima,Helen Monaghan,Rohina Joshi,Stephen Colagiuri,Mark E. Cooper,Paul Glasziou,Diederick E. Grobbee,Pavel Hamet,Stephen B. Harrap,Simon Heller,Liu Lisheng,Giuseppe Mancia,Michel Marre,David R. Matthews,Carl Erik Mogensen,Vlado Perkovic,Neil Poulter,Anthony Rodgers,Bryan Williams,Stephen MacMahon,Anushka Patel,Mark Woodward +27 more
TL;DR: There was no evidence that intensive glucose control during the ADVANCE factorial trial led to long-term benefits with respect to mortality or macrovascular events.
Journal ArticleDOI
Effect of finerenone on albuminuria in patients with diabetic nephropathy : a randomized clinical trial
George L. Bakris,Rajiv Agarwal,Juliana C.N. Chan,Mark E. Cooper,Ron T. Gansevoort,Hermann Haller,Giuseppe Remuzzi,Peter Rossing,Roland E. Schmieder,Christina Nowack,Peter Kolkhof,Amer Joseph,Alexander Pieper,Nina Kimmeskamp-Kirschbaum,Luis M. Ruilope +14 more
TL;DR: Finerenone demonstrated a dose-dependent reduction in UACR, and among patients with diabetic nephropathy, the addition of finerenone compared with placebo resulted in improvement in the urinary albumin-creatinine ratio.
Journal ArticleDOI
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes.
Mark E. Cooper,Dimitria Vranes,Sherif Youssef,Steven A. Stacker,Alison J. Cox,Bishoy Rizkalla,David J. Casley,Leon A. Bach,Darren J. Kelly,Richard E. Gilbert +9 more
TL;DR: Assessment of VEGF, 125I-VEGF binding, and vascular endothelial growth factor receptor-2 (VEGFR-2) in the kidney was performed after 3 and 32 weeks of streptozotocin-induced diabetes to indicate an early and persistent increase in renal V EGF gene expression in association with experimental diabetes.
Journal ArticleDOI
Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat
TL;DR: The concomitant changes in collagen-related fluorescence, albuminuria, and mesangial expansion with aminoguanidine therapy are consistent with the hypothesis that AGEs may play a role in the development of diabetic nephropathy.